The Clinical Need
A real-time point of care measurement of renal function has the potential to improve patient outcomes broadly across medical specialties. The unmet need in the critical care environment is well documented. Clinicians throughout the hospital are administering chemotherapy agents, antibiotics and contrast media that can cause kidney damage. Most of these medicines are highly nephrotoxic, and dosing is based on the perceived renal function of the patient.
Currently, there is no real-time point of care GFR measurement technique. This need for a real-time renal function measurement is recognized by the National Institutes for Health and is the subject of an on-going request to the medical research community for a solution.
The optimal solution for a real-time point of care GFR measurement technique will be:
- Easy to use
Patient populations impacted would be:
Intensive Care Unit
Treatment of acute kidney injury has been hampered by the inability of a creatinine-based diagnosis to allow clinicians to intervene with timely treatments aimed at preventing further development of the disease to the point where renal replacement therapy is necessary or death occurs.
AKI is a major complication of patients admitted to the ICU, with a mortality of 30-80%.
Acute kidney injury occurs in 4 to 20% of hospitalized patients and in 35 to 75% of critically ill patients in the Intensive Care Unit.
Chronic Kidney Disease
Patients can lose up to half their kidney function before diagnosis given current tests. Findings highlight the need to identify CKD in its earliest stages to prevent disease progression and avoid the high medical costs attributable to the latter stages of the disease.
Approximately 26 million US adults have CKD. CKD growth is expected as the population ages and the prevalence of diabetes and other risks increases among all age groups.
Diabetes is on the rise, and so is diabetic nephropathy. Given this epidemic, physicians should consider strategies to detect and control kidney disease in their diabetic patients.
Nephrotoxicity is the most important dose-limiting side effect of cisplatin…and occurs in 36% of patients after single doses…
The average in-hospital cost of CIN is $10,345. The 1-year cost of treating a patient with CIN is $11,812. Overall, the economic burden associated with CIN is high.
Contrast-Induced Nephropathy (CI-AKI) is the 3rd most common cause of hospital acquired AKI
Cardiac Catheterization Lab
Contrast-Induced Nephropathy will occur in 2% to 25% of patients undergoing coronary intervention.
Lengths of stay can be twice as long as the stays of patients without Contrast-Induced Nephropathy, and both inpatient and 30-day mortality can be as much as 10-fold greater.
In cardiac surgery, rates of kidney injury range between 7.7% and 11.4%.
A temporary decrease in kidney function occurs in approximately 5 to 10 percent of patients undergoing Coronary Artery Bypass Graft (CABG)
Early detection of graft dysfunction is paramount in determining reversibility from both medical and surgical complications.
For decades, renal function evaluation in small animal, primary care practice has been limited to measurements of SCr… However, these parameters are insensitive because they are altered only after 60% to 75% loss of renal function.